PRAME and leukemia: Choosing appropriate interventions can further improve the clinical outcomes of PRAME‐ and MRD‐positive patients.62 One study found that epigenetic upregulation of PRAME by a demethylating agent could lead to increased expression of PRAME, suggesting that epigenetic regulators in combination with specific CTA can improve the effect of immunotherapy in patients with AML.63 These results demonstrate that the PRAME protein could be processed by a demethylating agent and present on the cell surface of leukaemia cells and might be the target antigen for immunotherapy in leukaemia patients.